Biodetect (Xiamen) Biotechnology Co., LTD. Biodetect (Xiamen) Biotechnology Co., LTD. (hereinafter referred to as BioDetect) is located in Haicang National Biomedical Industrial Park. Founded by a group of overseas doctors, BioDetect is an innovative enterprise specializing in the research and development, production, sales and service of IVD reagents. BioDetect R&D team worked with technical force from Xiamen University, and successfully launched disposable virus sample tube, Rapid Sars-Cov-2 antigen test card, nucleic acid extracting reagent, nucleic acid extraction and purification reagent, and sample release agent, relying on the stability and good performance in the test, these products won the good reputation in the market. The disposable virus sample tube is CE certified and FDA registered. The rapid sars-cov-2 antigen test card has been certified by CE1434, FDA of Thailand and Malaysia MDA and also has obtained registration and entry permits from BfArm of Germany, ANSM of France, Ministry of Health of Italy, AEMPS of Spain and BASG of Austria. In 2017, BioDetect was selected into Xiamen "Double Hundred Plan" leading entrepreneurial talent project. In March 2017, BioDetect was selected into the Xiamen "Double hundred Plan" leading entrepreneurial talent project; In November 2022, BioDetect was awarded the national high-tech Enterprise; In April 2023, BioDetect Company was rated as a specialized special new small and medium-sized enterprise. BioDetect is an enterprise for the collection and storage of Municipal government, a white list enterprise for Provincial medical and epidemic prevention materials, and the supplier for the top-class hospital equipment; In June 2020, the company's quality management system passed ISO13485 certification.
|
Relying on the technical strength of Xiamen University, the company focuses on innovative constant temperature amplification/gene editing technology for rapid in vitro diagnosis. The company's products cover the detection of pathogenic microorganisms, genetic genes, and tumor mutation genes. |